Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Add as a preferred source on Google
REDWOOD CITY, Calif., Feb. 22, 2018 -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report fourth quarter and full year 2017 financial results and operational highlights on Thursday, March 8th, 2018. OncoMed management will host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing (855) 420-0692 (domestic) and (484) 756-4194 (international) using the conference ID# 4997704. The webcast of the conference call can be accessed live on the Investor Relations section of the OncoMed website, http://www.oncomed.com, and will be available for replay through June 30th, 2018.
An audio replay of the conference call can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP131-R10) and anti-TIGIT (OMP-313M32) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact:
Peter Rahmer
Trout Group
[email protected]
(646) 378-2973
Mike Zanoni
Trout Group
[email protected]
(646) 378-2924
